Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 27, 2017 (9 years ago)

Neostigmine Methylsulfate Injection in all strengths

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of sterility assurance.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Neostigmine Methylsulfate Injection in all strengths, all doses, and all packaging.

Drug: Neostigmine

Recalling firm
Pharmedium Services, LLC
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0461-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Neostigmine recalls

See all
Class II · Moderate risk

neostigmine 5 mg/5mL

Lack of assurance of sterility. Validation data for decontamination cycles is lacking.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. D-0982-2023

Other recalls by Pharmedium Services, LLC

All 2017 recalls